Stock Screener App

Gratuito -

5.80

9.64% +0.51

Foghorn Therapeutics Inc (FHTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché FHTX Giù? Forum Previsione

Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie

How To Trade (FHTX) - Stock Traders Daily

Stock Traders Daily

Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Foghorn Therapeutics Inc. (NASDAQ:FHTX) insider upped their holding by 2.2% earlier this year - Yahoo News UK

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target - Simply Wall St

Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength? - Yahoo Movies UK

Yahoo Movies UK

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target - Yahoo Finance

Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

(FHTX) Technical Data - Stock Traders Daily

Stock Traders Daily

Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ... - Yahoo Finance

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update - Yahoo Finance

Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect? - Yahoo Movies Canada

Yahoo Movies Canada

Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Reaffirmed by HC Wainwright - Defense World

Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - MarketBeat

Petri Dish: Non-viral vector startup launch; Foghorn's new CFO - Boston Business Journal - The Business Journals

The Business Journals

Foghorn Therapeutics Appoints Kristian Humer as New CFO - TipRanks.com - TipRanks

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer - Yahoo Finance

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth - Simply Wall St

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire Inc.

Foghorn Therapeutics Unveils Cancer Research Breakthroughs - TipRanks.com - TipRanks

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

GlobeNewswire Inc.

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Zacks Investment Research

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire Inc.

Have Insiders Sold Foghorn Therapeutics Shares Recently? - Simply Wall St

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Cambridge biotech discloses it quietly reduced staff by 28% last year - Boston Business Journal - The Business Journals

The Business Journals

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook - GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with ... - GlobeNewswire

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks Investment Research

VRTX: Dominate the Market With 3 Biotech Stocks - StockNews.com

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last? - Yahoo Finance

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Zacks Investment Research

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Zacks Investment Research

Lilly selects BRM-selective inhibitor for clinical development - BioWorld Online

BioWorld Online

FHTX Stock Quote Price and Forecast - CNN

Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product - MarketWatch

GILD: 3 Biotech Stock Gems Bursting With Buy Opportunities - StockNews.com

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 20% decline adds to one-year losses, institutional investors may consider drastic measures - Simply Wall St

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why

Zacks Investment Research

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%

Zacks Investment Research

Foghorn Therapeutics discovers new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online

BioWorld Online

Foghorn Therapeutics Names Quintás-Cardama Chief Medical Officer - Contract Pharma

Contract Pharma

Foghorn Therapeutics doses first patient in AML therapy trial - Clinical Trials Arena

Clinical Trials Arena

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update - Yahoo Finance

Foghorn downgraded to full clinical hold, with more patient deaths clouding AML, MDS trial - Fierce Biotech

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day - Yahoo Finance

How Eli Lilly's potential ~$1.7B partnership with Foghorn bolsters its oncology portfolio - Seeking Alpha

$77.45

3.66%

$147.20

0.22%

$29.77

1.52%

$169.85

3.01%

$93.02

0.95%

$374.35

0.70%

Apri su Yahoo | Apri su Google | Aperto in Finviz